Related papers: MethConvTransformer: A Deep Learning Framework for…
In recent years, deep learning models have been applied to neuroimaging data for early diagnosis of Alzheimer's disease (AD). Structural magnetic resonance imaging (sMRI) and positron emission tomography (PET) images provide structural and…
Characterizing the subtle changes of functional brain networks associated with the pathological cascade of Alzheimer's disease (AD) is important for early diagnosis and prediction of disease progression prior to clinical symptoms. We…
Alzheimer's disease (AD) is the most common neurodegenerative disease in older people. Despite considerable efforts to find a cure for AD, there is a 99.6% failure rate of clinical trials for AD drugs, likely because AD patients cannot…
Accurate diagnosis of Alzheimer's disease (AD) is essential for enabling timely intervention and slowing disease progression. Multimodal diagnostic approaches offer considerable promise by integrating complementary information across…
Alzheimer's disease and Frontotemporal dementia are two major types of dementia. Their accurate diagnosis and differentiation is crucial for determining specific intervention and treatment. However, differential diagnosis of these two types…
Early detection is a crucial goal in the study of Alzheimer's Disease (AD). In this work, we describe several techniques to boost the performance of 3D deep convolutional neural networks (CNNs) trained to detect AD using structural brain…
Reliable early detection of Alzheimer's disease (AD) is challenging, particularly due to limited availability of labeled data. While large language models (LLMs) have shown strong transfer capabilities across domains, adapting them to the…
Generative AI framework-based modeling and prediction of longitudinal human brain images offer an efficient mechanism to track neurodegenerative progression, essential for the assessment of diseases like Alzheimer's. Among the existing…
Alzheimer's disease (AD), defined as an abnormal buildup of amyloid plaques and tau tangles in the brain can be diagnosed with high accuracy based on protein biomarkers via PET or CSF analysis. However, due to the invasive nature of…
The aging population of the U.S. drives the prevalence of Alzheimer's disease. Brookmeyer et al. forecasts approximately 15 million Americans will have either clinical AD or mild cognitive impairment by 2060. In response to this urgent…
Generative modeling frameworks have emerged as an effective approach to capture high-dimensional image distributions from large datasets without requiring domain-specific knowledge, a capability essential for longitudinal disease…
Deep learning (DL) models have shown significant potential in Alzheimer's Disease (AD) classification. However, understanding and interpreting these models remains challenging, which hinders the adoption of these models in clinical…
Introduction: It is challenging at baseline to predict when and which individuals who meet criteria for mild cognitive impairment (MCI) will ultimately progress to Alzheimer's disease (AD) dementia. Methods: A deep learning method is…
Alzheimer's Disease (AD) is a progressive neurological disorder that can result in significant cognitive impairment and dementia. Accurate and timely diagnosis is essential for effective treatment and management of this disease. In this…
The current state-of-the-art deep neural networks (DNNs) for Alzheimer's Disease diagnosis use different biomarker combinations to classify patients, but do not allow extracting knowledge about the interactions of biomarkers. However, to…
Alzheimer's disease (AD) is associated with local (e.g. brain tissue atrophy) and global brain changes (loss of cerebral connectivity), which can be detected by high-resolution structural magnetic resonance imaging. Conventionally, these…
Alzheimer's Disease (AD) is an irreversible neurodegenerative disorder affecting millions of individuals today. The prognosis of the disease solely depends on treating symptoms as they arise and proper caregiving, as there are no current…
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by the progressive accumulation of misfolded proteins, leading to cognitive decline. This study presents a novel stochastic modelling approach to simulate the…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to cognitive decline. [$^{18}$F]-Fluorodeoxyglucose positron emission tomography ([$^{18}$F]-FDG PET) is used to monitor brain metabolism, aiding in the diagnosis…
Alzheimer's disease (AD) affects 50 million people worldwide and is projected to overwhelm 152 million by 2050. AD is characterized by cognitive decline due partly to disruptions in metabolic brain connectivity. Thus, early and accurate…